500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 145
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1.25M | 2.03M | 1956 |
Mr. Paul J. Mellett Jr. | Senior VP of Finance & Administration and CFO | 666.84k | 529.98k | 1955 |
Dr. Yat Sun Or Ph.D. | Senior VP of Research & Development and Chief Scientific Officer | 729.31k | 424.85k | 1952 |
Mr. Nathaniel S. Gardiner J.D. | Consultant | 672.67k | 49.14k | 1954 |
Mr. Brendan Luu | Senior Vice President of Business Development | 622.86k | N/A | 1975 |
Ms. Jennifer Viera | Senior Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Tara Lynn Kieffer Ph.D. | Senior Vice President of New Product Strategy & Development | 496.85k | N/A | 1978 |
Dr. Scott T. Rottinghaus M.D. | Senior VP & Chief Medical Officer | 616.73k | N/A | 1974 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 3; Board: 4; Shareholder rights: 8; Compensation: 7.